$INSM
INSMED Inc Stock $insm

$insm Overview Financials Valuation SEC Filings Company Website

2013 Q4 Form 10-Q Financial Statement

#000110465913080816 Filed on November 05, 2013

Income Statement

Concept	2013 Q4	2013 Q3	2012 Q3
Revenue	$0.00	$0.00	$0.00
YoY Change			-100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$5.970M	$4.750M	$3.650M
YoY Change	40.47%	30.14%	47.77%
% of Gross Profit
Research & Development	$9.630M	$12.10M	$5.706M
YoY Change	-16.91%	111.97%	-17.66%
% of Gross Profit
Depreciation & Amortization	$200.0K	$180.0K	$140.0K
YoY Change	33.33%	28.57%	75.0%
% of Gross Profit
Operating Expenses	$15.59M	$16.84M	$9.353M
YoY Change	-1.58%	80.07%	-0.61%
Operating Profit	-$15.59M	-$16.84M	-$9.353M
YoY Change	-1.54%	80.07%
Interest Expense	-$590.0K	$525.0K	$222.0K
YoY Change	-255.26%	136.49%	-40.0%
% of Operating Profit
Other Income/Expense, Net	-$40.00K	$0.00	$0.00
YoY Change
Pretax Income	-$16.21M	-$17.33M	-$9.382M
YoY Change	4.85%	84.68%	-72.88%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$16.21M	-$17.33M	-$9.382M
YoY Change	4.94%	84.68%	-72.88%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$413.6K	-$463.5K	-$375.0K
COMMON SHARES
Basic Shares Outstanding	39.11M shares	37.39M shares	25.01M shares
Diluted Shares Outstanding		37.39M shares	25.01M shares

Balance Sheet

Concept	2013 Q4	2013 Q3	2012 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$113.9M	$128.0M	$89.70M
YoY Change	22.6%	42.7%	7.81%
Cash & Equivalents	$113.9M	$128.0M	$44.99M
Short-Term Investments			$44.80M
Other Short-Term Assets	$2.300M	$1.700M	$600.0K
YoY Change	283.33%	183.33%	100.0%
Inventory
Prepaid Expenses
Receivables			$0.00
Other Receivables			$0.00
Total Short-Term Assets	$116.2M	$129.7M	$90.40M
YoY Change	24.13%	43.52%	7.62%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.812M	$1.904M	$1.600M
YoY Change	8.76%	19.0%	14.29%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments			$2.100M
YoY Change			0.0%
Other Assets	$300.0K	$100.0K	$100.0K
YoY Change	200.0%	0.0%	-75.0%
Total Long-Term Assets	$60.34M	$60.21M	$62.10M
YoY Change	0.59%	-3.05%	0.0%
TOTAL ASSETS
Total Short-Term Assets	$116.2M	$129.7M	$90.40M
Total Long-Term Assets	$60.34M	$60.21M	$62.10M
Total Assets	$176.5M	$190.0M	$152.5M
YoY Change	14.94%	24.56%	4.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.929M	$4.661M	$3.000M
YoY Change	-16.02%	55.37%	100.0%
Accrued Expenses	$3.905M	$5.652M	$2.700M
YoY Change	33.14%	109.33%	80.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$3.283M	$7.055M	$700.0K
YoY Change	9.18%	907.86%	600.0%
Total Short-Term Liabilities	$16.46M	$19.82M	$6.500M
YoY Change	4.5%	204.95%	75.68%
LONG-TERM LIABILITIES
Long-Term Debt	$16.34M	$12.54M	$8.600M
YoY Change	0.72%	45.79%
Other Long-Term Liabilities	$400.0K	$400.0K	$700.0K
YoY Change	-33.33%	-42.86%
Total Long-Term Liabilities	$16.34M	$12.54M	$9.300M
YoY Change	0.72%	34.82%
TOTAL LIABILITIES
Total Short-Term Liabilities	$16.46M	$19.82M	$6.500M
Total Long-Term Liabilities	$16.34M	$12.54M	$9.300M
Total Liabilities	$33.17M	$32.83M	$15.80M
YoY Change	1.51%	107.75%	327.03%
SHAREHOLDERS EQUITY
Retained Earnings	-$391.6M	-$375.4M
YoY Change	16.71%
Common Stock	$391.0K	$391.0K
YoY Change	24.13%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$143.3M	$157.1M	$136.6M
YoY Change
Total Liabilities & Shareholders Equity	$176.5M	$190.0M	$152.5M
YoY Change	14.94%	24.56%	4.38%

Cashflow Statement

Concept	2013 Q4	2013 Q3	2012 Q3
OPERATING ACTIVITIES
Net Income	-$16.21M	-$17.33M	-$9.382M
YoY Change	4.94%	84.68%	-72.88%
Depreciation, Depletion And Amortization	$200.0K	$180.0K	$140.0K
YoY Change	33.33%	28.57%	75.0%
Cash From Operating Activities	-$14.05M	-$16.29M	-$9.190M
YoY Change	57.51%	77.26%	14.73%
INVESTING ACTIVITIES
Capital Expenditures	-$120.0K	-$220.0K	-$20.00K
YoY Change	-29.41%	1000.0%	-95.92%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$2.160M	$0.00
YoY Change	-100.0%		-100.0%
Cash From Investing Activities	-$110.0K	$1.930M	-$30.00K
YoY Change	-100.25%	-6533.33%	-100.35%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$67.00M	$25.70M
YoY Change		160.7%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	40.00K	67.79M	25.63M
YoY Change	-99.61%	164.49%	-128250.0%
NET CHANGE
Cash From Operating Activities	-14.05M	-16.29M	-9.190M
Cash From Investing Activities	-110.0K	1.930M	-30.00K
Cash From Financing Activities	40.00K	67.79M	25.63M
Net Change In Cash	-14.12M	53.43M	16.41M
YoY Change	-130.83%	225.59%	2590.16%
FREE CASH FLOW
Cash From Operating Activities	-$14.05M	-$16.29M	-$9.190M
Capital Expenditures	-$120.0K	-$220.0K	-$20.00K
Free Cash Flow	-$13.93M	-$16.07M	-$9.170M
YoY Change	59.2%	75.25%	21.94%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Interest Paid InterestPaid	1416000	USD
CY2013Q3	us-gaap	Liabilities Current LiabilitiesCurrent	19822000	USD
CY2013Q3	us-gaap	Liabilities Liabilities	32825000	USD
CY2013Q3	us-gaap	Stockholders Equity StockholdersEquity	157125000	USD
CY2013Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	189950000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	90782000	USD
CY2012Q4	us-gaap	Certificates Of Deposit At Carrying Value CertificatesOfDepositAtCarryingValue	2153000	USD
CY2012Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	643000	USD
CY2012Q4	us-gaap	Assets Current AssetsCurrent	93578000	USD
CY2012Q4	us-gaap	Other Finite Lived Intangible Assets Gross OtherFiniteLivedIntangibleAssetsGross	58200000	USD
CY2012Q4	us-gaap	Other Assets OtherAssets	117000	USD
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1666000	USD
CY2012Q4	us-gaap	Assets Assets	153561000	USD
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	7060000	USD
CY2012Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2207000	USD
CY2012Q4	us-gaap	Accrued Rent Current AccruedRentCurrent	295000	USD
CY2012Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	149000	USD
CY2012Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	96000	USD
CY2012Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	3007000	USD
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	15747000	USD
CY2012Q4	us-gaap	Accrued Rent Noncurrent AccruedRentNoncurrent	647000	USD
CY2012Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	64000	USD
CY2012Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	16221000	USD
CY2012Q4	us-gaap	Liabilities Liabilities	32679000	USD
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	315000	USD
CY2012Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	455325000	USD
CY2012Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	790000	USD
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-335548000	USD
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	120882000	USD
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	153561000	USD
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	31488204	shares
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	31488204	shares
CY2013Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12095000	USD
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	2000	USD
	us-gaap	Revenues Revenues	11500000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-41080000	USD
CY2013Q3	us-gaap	Operating Expenses OperatingExpenses	16842000	USD
CY2012Q3	us-gaap	Operating Expenses OperatingExpenses	9353000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-32607000	USD
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	33577000	shares
	insm	Increase Decrease In Accrued Lease Expenses IncreaseDecreaseInAccruedLeaseExpenses	-193000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	786000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-22086000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	122000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	5000	USD
	us-gaap	Operating Expenses OperatingExpenses	50921000	USD
CY2013Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-17327000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	412000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1518000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	651000	USD
	insm	Increase Decrease In Accrued Liabilities And Deferred Rent Credit IncreaseDecreaseInAccruedLiabilitiesAndDeferredRentCredit	31000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	18190000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8410000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	55000	USD
CY2013Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-17327000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-39859000	USD
CY2012Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5706000	USD
CY2012Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3647000	USD
CY2013Q3	insm	Open Label Safety Study Period OpenLabelSafetyStudyPeriod	P2Y
CY2013Q3	insm	Number Of Initial Indications In Orphan Patient Populations For Which Clinical Trials Conducted NumberOfInitialIndicationsInOrphanPatientPopulationsForWhichClinicalTrialsConducted	2	item
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><b><i><font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Use of Estimates -</font></i></b> <font style="FONT-SIZE: 10pt;" size="2">The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes.  The Company bases its estimates and judgments on historical experience and on various other assumptions that it believes are reasonable under the circumstances.  The amounts of assets and liabilities reported in the Company’s balance sheets and the amounts of revenue and expenses reported for each period presented are effected by estimates and assumptions, which are used for, but not limited to, the accounting for revenue recognition, stock-based compensation, income taxes, loss contingencies, the warrant fair value calculation, impairment of intangibles and long lived assets and accounting for research and development costs.  Actual results could differ from those estimates.</font></p> <p style="MARGIN: 0in 0in 0pt;"> </p> </div>
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	item
CY2013Q3	us-gaap	Interest Payable Current InterestPayableCurrent	154000	USD
CY2013Q3	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	140000	USD
CY2013Q3	insm	Unamortized Discount From Warrant UnamortizedDiscountFromWarrant	437000	USD
CY2013Q3	us-gaap	Debt Current DebtCurrent	-7055000	USD
CY2013Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	12538000	USD
CY2013Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5652000	USD
CY2013Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	9519000	USD
CY2012Q4	insm	Liability For Stock Based Compensation Awards LiabilityForStockBasedCompensationAwards	1204000	USD
CY2012Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	185000	USD
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><b><i><font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Concentration of Credit Risk</font></i></b> <font style="FONT-SIZE: 10pt;" size="2">- Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents and short-term investments. The Company places its cash equivalents with financial institutions that it believes have high credit quality. The Company has established investment guidelines relative to credit ratings and maturities that seek to maintain safety and liquidity.</font></p> <p style="MARGIN: 0in 0in 0pt;"> </p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The Company sources each of its raw materials from a single supplier.  In addition, the production of the Company’s lead product candidate is performed by a sole manufacturer. The inability of the suppliers or manufacturer to fulfill supply requirements of the Company could materially adversely affect future operating results or the Company’s business generally. A change in the relationship with the suppliers or manufacturer, or an adverse change in their business, could materially adversely affect the Company’s future operating results.</font></p> <p style="MARGIN: 0in 0in 0pt;"> </p> </div>
CY2012Q4	us-gaap	Interest Payable Current InterestPayableCurrent	80000	USD
CY2012Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	4000	USD
CY2012Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2933000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-25923000	USD
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	33587000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	24916000	shares
CY2013Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37389000	shares
CY2012Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	25013000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	33587000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	24916000	shares
CY2013Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37389000	shares
CY2012Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	25013000	shares
CY2013Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.46
CY2012Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.38
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.19
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.04
CY2013Q3	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	0	USD
CY2012Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	0	USD
CY2013Q2	us-gaap	License And Services Revenue LicenseAndServicesRevenue	11500000	USD
CY2013Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2013Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-17327000	USD
CY2012Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9382000	USD
CY2013Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	30000	USD
CY2013Q3	us-gaap	Long Term Debt LongTermDebt	20000000	USD
CY2013Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	10451000	USD
CY2013Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2013Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2013Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	39100899	shares
CY2013Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	39100899	shares
CY2013Q3	us-gaap	Secured Debt SecuredDebt	20000000	USD
CY2013Q3	insm	Additional Charge At End Of Term AdditionalChargeAtEndOfTerm	170000	USD
CY2013Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	6900000	shares
CY2013Q3	insm	Common Stock Shares Exercise To Underwriters In Full Of Over Allotment Option CommonStockSharesExerciseToUnderwritersInFullOfOverAllotmentOption	900000	shares
CY2013Q3	us-gaap	Share Price SharePrice	10.40
CY2013Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	67017000	USD
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	343918	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	19100	shares
CY2013Q3	insm	Number Of Equity Compensation Plans NumberOfEquityCompensationPlans	3	item
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1817839	shares
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3438621	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1983800	shares
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	3197438	shares
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	387187	shares
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.10
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.36
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	9.84
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	4.28
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	10.03
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	7.33
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	3.81
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y1M28D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P9Y1M24D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y10M6D
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	28364114	USD
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	26490791	USD
CY2013Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	4570290	USD
CY2013Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	37389000	shares
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4000	USD
CY2013Q3	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.00	pure
CY2012Q3	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.00	pure
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.030	pure
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.00	pure
CY2012Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	350000000	USD
CY2013Q3	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	1201000	USD
CY2013Q3	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	498000	USD
CY2013Q3	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	425000	USD
CY2013Q3	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	2421000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	385000	USD
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	24916000	shares
CY2013Q3	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	200000	USD
CY2012Q3	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	200000	USD
CY2013Q3	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	297000	USD
CY2012Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9183000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-25538000	USD
CY2012Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	199000	USD
CY2012Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-9382000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-25919000	USD
CY2012Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	25013000	shares
	dei	Entity Registrant Name EntityRegistrantName	INSMED INC
	dei	Entity Central Index Key EntityCentralIndexKey	0001104506
	dei	Document Type DocumentType	10-Q
	dei	Document Period End Date DocumentPeriodEndDate	2013-09-30
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2013Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	39109854	shares
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
CY2013Q3	us-gaap	Assets Current AssetsCurrent	129745000	USD
CY2013Q3	us-gaap	Assets Assets	189950000	USD
	us-gaap	Operating Expenses OperatingExpenses	26600000	USD
CY2013Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-16842000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-39421000	USD
CY2012Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-9353000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-26600000	USD
CY2012Q3	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	193000	USD
	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	901000	USD
CY2012Q3	us-gaap	Interest Expense InterestExpense	222000	USD
	us-gaap	Interest Expense InterestExpense	225000	USD
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	5000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	1442000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	68408000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	37243000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	256000	USD
	us-gaap	Accretion Expense AccretionExpense	126000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-757000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	175000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	67017000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	16933000	USD
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	91000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1471000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	35294000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	30141000	USD
	us-gaap	Interest Paid InterestPaid	164000	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	4000	USD
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	385000	USD
	insm	Fair Value Of Warrants In Connection With Debt FairValueOfWarrantsInConnectionWithDebt	790000	USD
CY2013Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	128025000	USD
CY2012Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	44989000	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14848000	USD
CY2013Q3	insm	Fair Value Of Warrants Outstanding FairValueOfWarrantsOutstanding	790000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-39859000	USD
CY2013Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1720000	USD
CY2013Q3	us-gaap	Other Finite Lived Intangible Assets Gross OtherFiniteLivedIntangibleAssetsGross	58200000	USD
CY2013Q3	us-gaap	Other Assets OtherAssets	101000	USD
CY2013Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1904000	USD
CY2013Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	4661000	USD
CY2013Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1953000	USD
CY2013Q3	us-gaap	Accrued Rent Current AccruedRentCurrent	303000	USD
CY2013Q3	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	134000	USD
CY2013Q3	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	64000	USD
CY2013Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	7055000	USD
CY2013Q3	us-gaap	Accrued Rent Noncurrent AccruedRentNoncurrent	449000	USD
CY2013Q3	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	16000	USD
CY2013Q3	us-gaap	Common Stock Value CommonStockValue	391000	USD
CY2013Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	532141000	USD
CY2013Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-375407000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	34654000	USD
CY2013Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4747000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	16267000	USD
CY2013Q3	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	40000	USD
	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	141000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1078000	USD
	us-gaap	Interest Expense InterestExpense	1802000	USD
CY2013Q3	us-gaap	Interest Expense InterestExpense	525000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	475000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	6410000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2399000	USD
	insm	Increase Decrease In Accrued Liabilities And Deferred Rent Credit IncreaseDecreaseInAccruedLiabilitiesAndDeferredRentCredit	3908000	USD
	insm	Increase Decrease In Accrued Lease Expenses IncreaseDecreaseInAccruedLeaseExpenses	-190000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-254000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	713000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	2000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	25659000	USD
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	80000	USD
	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	9726000	USD
CY2013Q4	insm	Number Of Patients Enrolled In Clinical Trials Conducted NumberOfPatientsEnrolledInClinicalTrialsConducted	90	item
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	2153000	USD
CY2013Q3	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	4700000	USD
CY2013Q3	insm	Accrued Clinical Trial Expenses And Manufacturing Expenses Current AccruedClinicalTrialExpensesAndManufacturingExpensesCurrent	5033000	USD
CY2012Q4	insm	Accrued Clinical Trial Expenses And Manufacturing Expenses Current AccruedClinicalTrialExpensesAndManufacturingExpensesCurrent	1460000	USD
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	17050000	USD
CY2012Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD

Files In Submission

Name	View Source	Status
0001104659-13-080816-index-headers.html	Edgar Link	pending
0001104659-13-080816-index.html	Edgar Link	pending
0001104659-13-080816.txt	Edgar Link	pending
0001104659-13-080816-xbrl.zip	Edgar Link	pending
a13-19824_110q.htm	Edgar Link	pending
a13-19824_1ex10d1.htm	Edgar Link	pending
a13-19824_1ex10d2.htm	Edgar Link	pending
a13-19824_1ex31d1.htm	Edgar Link	pending
a13-19824_1ex31d2.htm	Edgar Link	pending
a13-19824_1ex32d1.htm	Edgar Link	pending
a13-19824_1ex32d2.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
insm-20130930.xml	Edgar Link	completed
insm-20130930.xsd	Edgar Link	pending
insm-20130930_cal.xml	Edgar Link	unprocessable
insm-20130930_def.xml	Edgar Link	unprocessable
insm-20130930_lab.xml	Edgar Link	unprocessable
insm-20130930_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$INSM
INSMED Inc Stock $insm

2013 Q4 Form 10-Q Financial Statement

#000110465913080816 Filed on November 05, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INSM INSMED Inc Stock $insm

2013 Q4 Form 10-Q Financial Statement

#000110465913080816 Filed on November 05, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INSM
INSMED Inc Stock $insm